Floatz logo

Troxacitabine

Neoplasms

SGX Pharmaceuticals, Inc.Small moleculePhase 1/2Dormant
D
24/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
11/ 100
Competitive Position
65/ 100

Competitive context

928 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Troxacitabine is also rated in:

acute myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →
acute myeloid leukemiaDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →